Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN V vs KEPIVANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
Infections caused by susceptible strains of bacteria including rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, and spirochetes,Acne vulgaris,Adjunctive therapy in severe acne,Off-label: Chronic prostatitis, sclerosing keratitis, rosacea
FDA-approved: To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.,Off-label: Prevention of oral mucositis in other cancers; management of acute radiation-induced mucositis.
250-500 mg orally every 6 hours
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (Cr Cl <30 m L/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration; small amount metabolized in liver.
Metabolized via proteolytic degradation; no specific CYP450 involvement.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
50-65% bound to serum albumin; primarily binds to alpha-1-acid glycoprotein.
Approximately 95% bound to plasma proteins, primarily albumin.
1.5-2.0 L/kg (large volume indicates extensive tissue distribution, concentrating in bile, liver, kidneys, and bone; minimal CNS penetration despite lipophilicity).
Volume of distribution at steady state (Vd_ss) is approximately 0.2 L/kg, indicating limited extravascular distribution, consistent with a large protein-bound molecule. Does not distribute extensively into tissues.
Oral: 60-80% (reduced by food, particularly dairy products, due to chelation with divalent cations). Intravenous: 100%.
Subcutaneous administration: Absolute bioavailability is approximately 90% compared to intravenous administration. Not available orally; only given subcutaneously.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: 250-500 mg every 12-24 hours; GFR <10 m L/min: 250-500 mg every 24 hours
No dose adjustment is recommended for renal impairment, but monitor serum creatinine.
No dosage adjustment required; use with caution in severe hepatic impairment due to potential hepatotoxicity
No specific dose adjustment for Child-Pugh class A or B; use caution in severe impairment.
Children >8 years: 25-50 mg/kg/day orally divided every 6 hours
Safety and efficacy not established; no recommended pediatric dose.
Consider age-related renal impairment; adjust dose based on GFR; avoid if possible due to increased risk of photosensitivity and gastrointestinal effects
No specific dose adjustment, but consider age-related renal and hepatic function decline.
Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent discoloration of teeth (yellow-gray-brown).
None.
Photosensitivity manifested by exaggerated sunburn reaction,Renal impairment may lead to drug accumulation and potential hepatotoxicity,Superinfection with resistant organisms including fungi,Bone growth retardation in premature infants,Pseudotumor cerebri (benign intracranial hypertension) in adults
Potential for stimulation of epithelial tumor growth (use caution in patients with non-hematologic malignancies).,Risk of allergic reactions including anaphylaxis.,May cause oral mucosal thickening and dental abnormalities.,Avoid use within 24 hours before or after myelotoxic chemotherapy.
Hypersensitivity to tetracyclines,Pregnancy,Children under 8 years of age,Severe renal or hepatic impairment
Hypersensitivity to palifermin or any excipients.,Concurrent use within 24 hours of myelotoxic chemotherapy.
Avoid dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-4 hours of dosing. Also avoid concurrent intake of iron-rich foods or supplements, zinc, magnesium, and antacids. High-fat meals may reduce absorption; take on an empty stomach.
No specific food interactions have been reported for KEPIVANCE. Maintain adequate nutrition and hydration as recommended by your healthcare provider.
Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Reversible inhibition of bone growth has been reported. First-trimester exposure is associated with a small risk of neural tube defects and other malformations in some studies. Avoid use during pregnancy unless for serious infections (e.g., anthrax, brucellosis) when alternative antibiotics are contraindicated.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (IV), which produced exposures approximately 40 and 80 times the human exposure at the recommended clinical dose of 60 mcg/kg/day, based on AUC. However, there are no human data. Risk in first trimester: unknown; second and third trimesters: unknown.
Tetracycline is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.6–0.8. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. Short-term use at recommended doses is generally considered compatible with breastfeeding by the American Academy of Pediatrics, but prolonged or repeated courses should be avoided. Monitor infant for potential gastrointestinal disturbances or rash.
It is not known whether palifermin is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from palifermin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy reduces tetracycline serum concentrations due to increased volume of distribution and enhanced hepatic clearance. However, dose adjustments are not routinely recommended because the drug is generally avoided in pregnancy. If use is unavoidable (e.g., anthrax), standard adult doses (e.g., 250-500 mg every 6 hours) may be insufficient; consider monitoring serum levels if available and adjusting based on clinical response. Avoid in the second and third trimesters if possible.
No pharmacokinetic data in pregnancy. No dose adjustment recommendations are provided for pregnancy; use only if clearly needed.
Tetracycline chelates with divalent and trivalent cations; avoid concurrent administration with dairy, antacids, iron, or calcium supplements. Photosensitivity risk: advise sun avoidance and use of sunscreen. Monitor renal function in elderly; adjust dose in severe renal impairment. Not for use in pregnancy or children under 8 years due to tooth discoloration and bone growth inhibition. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor used to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy requiring hematopoietic stem cell support. Administer as a 3-day course of 60 mcg/kg/day IV bolus for 3 consecutive days before and 3 consecutive days after myelotoxic therapy. Must be given at least 24 hours before and after chemotherapy; do not administer within 24 hours of chemotherapy due to risk of enhanced cytotoxicity. Monitor for skin reactions, oral/perioral edema, and taste alteration. Contraindicated in patients with known hypersensitivity to E. coli-derived proteins.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium supplements within 2-4 hours of taking this drug.,Protect your skin from sun exposure; use sunscreen and wear protective clothing as this medicine can cause severe sunburn.,Do not take this drug if you are pregnant or breastfeeding; it can harm the baby's teeth and bones.,Complete the full course of treatment even if you feel better; do not skip doses.,Report any signs of allergic reaction, severe headache, blurred vision, or persistent diarrhea to your doctor immediately.,Store at room temperature away from moisture and light.
KEPIVANCE reduces the severity and duration of mouth sores caused by high-dose chemotherapy.,It is given as a short intravenous infusion once daily for 3 days before and 3 days after your chemotherapy.,You may experience swelling of the mouth, tongue, or lips; skin rash; or changes in taste. Report these to your healthcare team.,Do not receive KEPIVANCE within 24 hours before or after chemotherapy.,Inform your doctor if you have any allergies, especially to E. coli-derived products.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN V vs KEPIVANCE, answered by our medical review team.
ACHROMYCIN V is a Tetracycline Antibiotic that works by Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.. KEPIVANCE is a Growth Factor that works by Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN V and KEPIVANCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN V is: 250-500 mg orally every 6 hours. The standard adult dose of KEPIVANCE is: 60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN V and KEPIVANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN V is classified as Category C. Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth. KEPIVANCE is classified as Category C. KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.